Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category.
美国银行证券公司已提升Inspire医疗系统公司的评级（纽交所：INSP），并表示该公司现在属于盈利增长类别。
Inspire Medical is expected to give its 2025 revenue guidance in early January, likely alongside its fourth-quarter results.
Inspire医疗预计将在1月初提供2025年的营业收入指引，可能与其第四季度业绩一起发布。
The company has already stated that it is comfortable with the Street's consensus of $950 million in revenue for 2025.
该公司已经表示，它对市场达成共识的2025年营业收入为95000万感到满意。
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.
对于2024年，该公司预计销售额将在79300万至79800万之间，而之前的指引为78800万至79800万，市场共识为79609万。
BofA has upgraded the stock from Neutral to Buy with a price target of $255, up from $220.
美国银行已将此股票的评级从中立上调至买入，目标价格从220美元上调至255美元。
Inspire Medical's outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
Inspire医疗对2025年的展望基于招聘更多员工、开设新中心、增加直接面向消费者的广告、扩大治疗适应症和提升产能的计划。
Also Read: FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious
另请阅读：FDA将Inspire医疗的睡眠呼吸暂停神经刺激器召回标记为最严重。
The Inspire V system, expected to make a bigger impact in the second half of 2025 after the Inspire IV to V transition, could make the procedure easier and more accessible to more doctors, including general surgeons, ENTs, and neurosurgeons.
Inspire V系统预计在2025年下半年更大影响力，将使手术对更多医生（包括普通外科医生、耳鼻喉科医生和神经外科医生）变得更简单、更可及。
In August, the FDA approved the Inspire V therapy system, which includes the next-generation neurostimulator and the associated Bluetooth patient remote and physician programmer.
在八月，FDA批准了Inspire V治疗系统，该系统包括下一代神经刺激器和相关的蓝牙患者遥控器及医生编程器。
The company targets a soft launch in late 2024 and a full launch in 2025
该公司计划在2024年底进行软启动，并在2025年进行全面启动。
One major advantage of Inspire V is that it simplifies the procedure by eliminating the need to place the sensing lead, which was a more complicated part of the process.
Inspire V的一个主要优势是简化了手术，因为不需要放置传感导线，这曾是过程中的一个更复杂的部分。
The analyst writes, "There are limited smid cap profitable growth stocks with a new product story in 2025 and INSP screens attractive as we look for top smid cap ideas in 2025. INSP seems on the path towards double digit margins which is when valuations tend to inflect and strategic interest increases."
分析师写道：“在2025年，只有有限的中型市值盈利成长股票具有新的产品故事，而INSP作为我们在2025年寻找的顶级中型市值创意显得很有吸引力。INSP似乎正在朝着两位数的利润率迈进，而这通常会导致估值变化和战略兴趣增加。”
Price Action: INSP stock is up 4.90% at $184.67 at last check Wednesday.
价格动态：截至周三最后一次检查，INSP股票上涨4.90%，报184.67美元。
Photo by Ground Picture on Shutterstock
来自Shutterstock的Ground Picture拍摄的照片
- What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone?
- 在拒绝达能修订收购提议后，Lifeway股票有什么变化？
